PICO

15 results

Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Feng F, Huang J, Wang Z, Zhang J, Han D, Wu Q, He H, Zhou X - BMC complementary medicine and therapies, February 06, 2020 14 citations

NSCLC patients

I/C

Xiao-ai-ping injection (XAPI) + platinum-based chemotherapy, platinum-based chemotherapy alone

objective tumor response rate (ORR), Karnofsky performance scores (KPS), occurrence of grade 3/4 leukopenia, anemia, thrombocytopenia, nausea and vomiting, immune function (CD8)

Pan-immune inflammation value as a prognostic biomarker for cancer patients treated with immune checkpoint inhibitors.

Kuang T, Qiu Z, Wang K, Zhang L, Dong K, Wang W - Frontiers in immunology, February 27, 2024 1 citations

cancer patients

I/C

immune checkpoint inhibitors (ICIs), higher PIV

shorter overall survival (OS) and progression-free survival (PFS)

Genetically Determined Circulating Lactase/Phlorizin Hydrolase Concentrations and Risk of Colorectal Cancer: A Two-Sample Mendelian Randomization Study.

Han S, Yao J, Yamazaki H, Streicher SA, Rao J, Nianogo RA, Zhang Z, Huang BZ - Nutrients, March 28, 2024 0 citations

Fenland Study, FinnGen Study, PLCO Atlas Project, Pan-UK Biobank

I/C

lactase-phlorizin hydrolase (LPH), colorectal cancer (CRC)

direct causal relationship

Pan-American prevalence of smokeless tobacco use and association with oral potentially malignant disorders and head and neck cancer: a systematic review and meta-analysis.

Pedroso CM, Normando AGC, Siracusa CS, Lauby-Secretan B, Nethan ST, Tomasi RA, Lopes MA, Warnakulasuriya S, Santos-Silva AR - Oral surgery, oral medicine, oral pathology and oral radiology, April 20, 2023 2 citations

pediatric, adult

I/C

smokeless tobacco (SLT), oral potentially malignant disorders (OPMDs), head and neck cancer (HNC)

prevalence of use, association

Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis.

Haraka F, Kakolwa M, Schumacher SG, Nathavitharana RR, Denkinger CM, Gagneux S, Reither K, Ross A - The Cochrane database of systematic reviews, June 08, 2021 6 citations

people being investigated for tuberculosis

I/C

Xpert MTB/RIF, smear microscopy

mortality, proportion of participants starting tuberculosis treatment who had a successful treatment outcome, proportion of participants who were treated for tuberculosis, proportion of participants with bacteriological confirmation who were lost to follow-up pre-treatment, proportion of treated participants who had bacteriological confirmation

Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

Roustaei H, Kiamanesh Z, Askari E, Sadeghi R, Aryana K, Treglia G - Contrast media & molecular imaging, March 15, 2022 19 citations

patients with oncologic and nononcologic indications

I/C

FAP-specific PET imaging and radionuclide therapy, detection rates of FAPI avidity

high radiolabeled FAPI avidity as early as 10 minutes after administration in primary sites of various malignant tumors

Combined Orthodontic-Surgical Treatment May Be an Effective Choice to Improve Oral Health-Related Quality of Life for Individuals Affected With Severe Dentofacial Deformities.

Gandedkar NH, Darendeliler MA - The journal of evidence-based dental practice, September 15, 2020 4 citations

Orthodontic-surgical treatment patients

I/C

Conventional combined orthodontic-surgical treatment, No treatment or alternative treatments

Oral health-related quality of life

The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data.

Luciano L, Annunziata M, Attolico I, Di Raimondo F, Maggi A, Malato A, Martino B, Palmieri F, Pane F, Sgherza N, Specchia G - European journal of haematology, March 08, 2020 15 citations

patients with chronic myeloid leukemia (CML)

I/C

ponatinib, a third-generation TKI, current first-line TKIs

effectiveness, feasibility, and safety of ponatinib in real-life clinical management of CML

A systematic review and meta-analysis of long noncoding RNA 00963 expression and prognosis and clinicopathological characteristic in human cancers.

He J, Wang Z, Wang Y, Liu F, Fu L, Jiang X, Wang P, Chen H, Hu M, Cai H - Pathology, research and practice, January 26, 2023 1 citations

human tumors

I/C

LINC00963 expression, poor overall survival

MSI, TMB, MMR

Pharmacologic and genetic inhibition of cholesterol esterification enzymes reduces tumour burden: A systematic review and meta-analysis of preclinical models.

Websdale A, Kiew Y, Chalmers P, Chen X, Cioccoloni G, Hughes TA, Luo X, Mwarzi R, Poirot M, Røberg-Larsen H, Wu R, Xu M, Zulyniak MA, Thorne JL - Biochemical pharmacology, August 19, 2021 6 citations

tumour tissue, non-tumour tissue

I/C

pharmacological or genetic inhibition of SOAT, tumour tissue vs non-tumour tissue

significantly smaller tumours of all types, increased tumour apoptosis, CD8+ lymphocyte infiltration and cytotoxicity, reduced proliferation, reduced metastasis

Papers